Oculis Holding AG (OCS) Income from Continuing Operations (2022 - 2026)
Quarterly Income from Continuing Operations changed 0.46% to 37094432.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 21033180158.89 through Mar 2026, up 9.94% year-over-year, with the annual reading at 124277444.25 for FY2025, 26.45% down from the prior year.
Oculis Holding AG's Income from Continuing Operations history spans 5 years, with the latest figure at 37094432.0 for Q1 2026.
- Income from Continuing Operations came in at 37094432.0 for Q1 2026, down from 72715485.96 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 72715485.96 in Q4 2025 to a low of 23261892784.97 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 21477057.43 (2023), against an average of 2783551865.92.
- Year-over-year, Income from Continuing Operations plummeted 116344.35% in 2024 and then skyrocketed 318.67% in 2025.
- Oculis Holding AG's Income from Continuing Operations stood at 9561219.83 in 2022, then crashed by 47.68% to 14120114.78 in 2023, then plummeted by 135.51% to 33253672.96 in 2024, then surged by 318.67% to 72715485.96 in 2025, then plummeted by 151.01% to 37094432.0 in 2026.
- Per Business Quant, the three most recent readings for OCS's Income from Continuing Operations are 37094432.0 (Q1 2026), 72715485.96 (Q4 2025), and 21038093019.56 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | -37.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.09 Mn |
| Dec 31, 2025 | 72.72 Mn |
| Sep 30, 2025 | -21.04 Bn |
| Jun 30, 2025 | -30.71 Mn |
| Mar 31, 2025 | -36.93 Mn |
| Dec 31, 2024 | -33.25 Mn |
| Sep 30, 2024 | -23.26 Bn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -18.37 Mn |
| Dec 31, 2023 | -14.12 Mn |
| Sep 30, 2023 | -19.98 Mn |
| Jun 30, 2023 | -14.07 Mn |
| Mar 31, 2023 | -49.48 Mn |
| Dec 31, 2022 | -9.56 Mn |
| Sep 30, 2022 | -10.29 Mn |
| Jun 30, 2022 | -12.73 Mn |